DKSH Business Unit Healthcare has announced a strategic distribution partnership with BridgeBio, a biotechnology company specialising in genetic diseases. This collaboration aims to facilitate the regulatory evaluation and potential patient access to a transthyretin stabiliser for transthyretin-mediated amyloidosis (ATTR-CM) across Australia, Singapore, South Korea, and Taiwan. The partnership combines BridgeBio’s biotech innovation with DKSH’s comprehensive commercialisation platform.
The transthyretin stabiliser is intended for treating cardiomyopathy in adults with wild-type or variant ATTR-CM, a progressive disease that significantly impacts quality of life and can lead to premature death. Currently, the treatment is not approved in the regions covered by the agreement, and its commercialisation will depend on obtaining necessary regulatory approvals.
DKSH will leverage its expertise in regulatory affairs, medical affairs, market access, and distribution to support the introduction of this treatment. Patrik Grande, Global Head of Business Unit Healthcare at DKSH, stated, “Our strategic partnership with BridgeBio represents an important milestone as DKSH Healthcare enters a new chapter with a renewed vision for growth.”
With over 160 years of experience, DKSH is a leading provider of Market Expansion Services, operating in 35 markets with a workforce of 26,840 specialists. In 2025, DKSH’s Business Unit Healthcare generated net sales of CHF 5.8 billion, distributing pharmaceuticals, consumer health products, and medical devices. This partnership marks a significant step in expanding access to innovative treatments in the Asia-Pacific region.
